AAAhmed Ammar

Ahmed Ammar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ahmed Ammar has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Imaging‐Guided Versus Conventional Ventricular Tachycardia Ablation in Ischemic Cardiomyopathy: A Systematic Review and Meta‐Analysis

    by Sabbir Ahmed, Khalid Sawalha, Mohamed Sharief, Ahmed Ammar

    Advanced cardiac imaging can characterize infarct substrate and guide ablation strategy and lesion delivery during ventricular tachycardia (VT) ablation, but its incremental benefit over conventional strategies in ischemic cardiomyopathy (ICM) remains uncertain. We compared imaging‐guided with conventional VT ablation in adults with ICM. This PRISMA‐compliant systematic review and meta‐analysis was registered in PROSPERO (CRD420261399180). MEDLINE, Cochrane CENTRAL, and Scopus were searched from January 1, 2016, through May 21, 2026, with citation tracking. Comparative analyses were restricted to ICM populations or extractable ICM subgroups. The primary outcome was VT recurrence, pooled using random‐effects risk ratios (RRs); single‐arm imaging‐guided cohorts were summarized descriptively. Four comparative studies included 316 patients, of whom 134 underwent imaging‐guided ablation and 182 underwent conventional ablation. Imaging‐guided ablation was associated with lower VT recurrence (pooled RR 0.53, 95% confidence interval 0.36–0.79; p = 0.002; I 2 = 0%), with consistent effects across imaging modalities and study designs. Major complications were infrequent and numerically similar between groups, although sparse events and heterogeneous definitions precluded pooling. Three additional single‐arm imaging‐guided studies reported favorable VT‐free or event‐free survival, acceptable safety, and high acute non‐inducibility, but were not used to infer comparative efficacy. In patients with ICM undergoing scar‐related VT ablation, imaging‐guided ablation was associated with lower VT recurrence without an apparent increase in major complications; given the limited comparative evidence, these findings are hypothesis‐generating rather than practice‐changing. Larger multicenter randomized trials are required to confirm the magnitude of benefit and define patient selection, imaging modality, and integration strategy.

  • Open Access

    Accuracy of non-invasive electrocardiographic imaging in scar-dependent ventricular tachycardia: relationship to arrhythmogenic substrate and imaging defined scar

    by Jaffar Al-Sheikhli, Xuezhe Wang, Joseph Mayer, Mohamed Anwar Mohamed, Syed Rizwan Ali, Rafaella Siang, May Thant, Ian Patchett, Ahmed Ammar, John Silberbauer, et al.

    Aims: Accuracy data for non-invasive electrocardiographic imaging (ECGi) in defining the arrhythmogenic substrate for scar-dependent ventricular tachycardia (VT) is lacking. This study evaluated the accuracy of ECGi mapping to localize the arrhythmogenic substrate and assessed the relationship to myocardial scar, isthmus, exit, and successful ablation sites. Methods and results: A total of 48 VTs in 31 patients were mapped with both ECGi (View into Ventricular Onset, VIVO) and electro-anatomical maps (EAM) to define the arrhythmogenic substrate. Myocardial segments were assigned for the VT-exit site region (VT-ESR), isthmus region, successful ablation sites, and cardiac cross-sectional imaging defined scar using the ventricular AHA segment model and underwent blinded analysis. VT-ESR complete match (defined as exact AHA segment concordance between ECGi and EAM) was seen in 67% and partial match (defined as adjacent segments) in 21% of VTs. ECGi VT-ESR was located within or adjacent to cross-sectional imaging defined scar in 85% of VTs. The VT isthmus was within or adjacent to the ECGi VT-ESR in 77% of VTs. Successful ablation sites were within or adjacent to the ECGi VT-ESR in 82% of VTs. VIVO ECGi accuracy was not affected by cardiomyopathy type or VT cycle length. In identifying epicardial VT-ESR for ischaemic cardiomyopathy, VIVO ECGi had a sensitivity and specificity of 71.4% and 92.9%; for non-ischaemic cardiomyopathy 66.7% and 100%, respectively. Conclusion: ECGi mapping with VIVO can accurately predict the arrhythmogenic substrate for scar-dependent VT. Incorporation of ECGi mapping to conventional VT ablation workflows may improve procedural efficiency.


  • Open Access

    Outcomes of Pulsed Field Versus Cryoballoon Ablation in Atrial Fibrillation: A Comprehensive Systematic Review and Meta‐Analysis

    by Omnia Kamel, Khalid Sawalha, Mohamed Abdelazem, Amir Abdelghany, Maha Elsaid, Mohamed Sharief, Ahmed Ammar

    Background: Catheter‐based pulmonary vein isolation (PVI) is an established treatment for atrial fibrillation (AF). While cryoballoon ablation (CBA) is a well‐validated single‐shot thermal technology, pulsed field ablation (PFA) has emerged as a predominantly non‐thermal modality that employs high‐voltage electric fields to achieve selective myocardial ablation, potentially minimizing collateral damage. However, comparative evidence between PFA and CBA remains limited. Objectives: To systematically review and compare the efficacy, safety, and procedural efficiency of PFA versus CBA for PVI. Methods and Results: A structured systematic database search was conducted up to August 2025, following PRISMA guidelines. Eighteen studies ( n = 5638; 2396 PFA and 3242 CBA) were included including two randomized controlled trials. PFA significantly shortened procedure time (mean difference −13.7 min; 95% CI –16.7 to −10.8; p < 0.001), while fluoroscopy time and radiation dose were similar. Both modalities achieved high acute PVI success (95%–100%). At 12‐month follow‐up, PFA showed lower arrhythmia recurrence (OR 0.73; 95% CI 0.59–0.90; p = 0.003) with no difference in redo ablation. Overall complications were fewer with PFA (OR 0.53; 95% CI 0.32–0.87; p < 0.001), largely due to reduced phrenic nerve injury, though cardiac tamponade occurred slightly more often in the PFA group. Subgroup analyzes yielded consistent results in paroxysmal AF and when 3D mapping was used. Conclusion: PFA offers superior procedural efficiency and safety compared with CBA, achieving shorter procedures, fewer complications, and lower arrhythmia recurrence at mid‐term follow‐up. Larger multicentre randomized trials with standardized protocols and long‐term follow‐up are needed to confirm these findings and evaluate evolving PFA technologies.


  • Open Access

    Outcomes of Catheter Ablation of Ventricular Tachycardia in Non-Ischaemic Cardiomyopathy A Systematic review and meta-analysis

    by Ahmed Ammar, Mohamed Sharief, Khaled Abouelmagd, Omar Riad, Mokhtar Ibrahim

    Background: Catheter Ablation (CA) of Ventricular Tachycardia (VT) in patients with Non-Ischaemic Cardiomyopathy (NICM) is a well-known line of treatment to prevent recurrence of VT and ICD shocks. Objective: To perform a systematic review and meta-analysis of available trials regarding the outcomes of VT ablation in patients with NICM. Methods: A comprehensive database search of large four electronic databases, including PubMed, Cochrane, Scopus, and Institute for Scientific Information network meta-analysis, identified ten studies enrolling 16370 patients for patients with NICM underwent CA for VT. The short-term outcomes assessed included procedural success, VT non-inducibility and procedural complications, whereas the long-term outcomes assessed included VT recurrence, repeat ablation procedures, heart transplantation, and death. Results:  A total of 10 observational studies reported outcomes in 16370 patients with NICM undergoing VT catheter ablation. Idiopathic dilated cardiomyopathy (IDCM) was the most frequently reported etiology of NICM (60.2%) and the duration of follow up ranged from 12 to 49 months. The complete procedural success was moderately high; 57.3% (95% CI 0.493-0.652) with VT non-inducibility observed in 63.5% of the patients (95% CI 0.434-0.836), major complications up to 6% (95% CI 0.055-0.079) and in-hospital death up to 1.5% (95% CI (0.003-0.027). The long-term outcomes showed an estimate of 44.5% for VT recurrence (95% CI 0.331-0.558), 18.2% for death (95% CI 0.123-0.559) and 7% for heart transplantation (95% CI 0.030-0.110). Conclusion: The meta-analysis showed that VT catheter ablation in NICM is safe and effective approach for management of patients with NICM and VT with wide discrepancy in the reported short and long-term outcomes after VT ablation likely because of the heterogeneous VT substrates in each etiology and the different VT ablation strategies.

  • Open Access

    Antiplatelet and Anti-Coagulation Therapy for Left-Sided Catheter Ablations: What Is beyond Atrial Fibrillation?

    by Martina Nesti, Fabiana Lucà, David Duncker, Francesco De Sensi, Katarzyna Malaczynska-Rajpold, Jonathan M. Behar, Victor Waldmann, Ahmed Ammar, Gianluca Mirizzi, Rodrigue Garcia, et al.

    Aim: International guidelines on the use of anti-thrombotic therapies in left-sided ablations other than atrial fibrillation (AF) are lacking. The data regarding antiplatelet or anticoagulation strategies after catheter ablation (CA) procedures mainly derive from AF, whereas for the other arrhythmic substrates, the anti-thrombotic approach remains unclear. This survey aims to explore the current practices regarding antithrombotic management before, during, and after left-sided endocardial ablation, not including atrial fibrillation (AF), in patients without other indications for anti-thrombotic therapy. Material and Methods: Electrophysiologists were asked to answer a questionnaire containing questions on antiplatelet (APT) and anticoagulation therapy for the following left-sided procedures: accessory pathway (AP), atrial (AT), and ventricular tachycardia (VT) with and without structural heart disease (SHD). Results: We obtained 41 answers from 41 centers in 15 countries. For AP, before ablation, only four respondents (9.7%) used antiplatelets and two (4.9%) used anticoagulants. At discharge, APT therapy was prescribed by 22 respondents (53.7%), and oral anticoagulant therapy (OAC) only by one (2.4%). In patients with atrial tachycardia (AT), before ablation, APT prophylaxis was prescribed by only four respondents (9.7%) and OAC by eleven (26.8%). At discharge, APT was recommended by 12 respondents (29.3%) and OAC by 24 (58.5%). For VT without SHD, before CA, only six respondents (14.6%) suggested APT and three (7.3%) suggested OAC prophylaxis. At discharge, APT was recommended by fifteen respondents (36.6%) and OAC by five (12.2%). Regarding VT in SHD, before the procedure, eight respondents (19.5%) prescribed APT and five (12.2%) prescribed OAC prophylaxis. At discharge, the administration of anti-thrombotic therapy depended on the LV ejection fraction for eleven respondents (26.8%), on the procedure time for ten (24.4%), and on the radiofrequency time for four (9.8%), with a cut-off value from 1 to 30 min. Conclusions: Our survey indicates that the management of anti-thrombotic therapy surrounding left-sided endocardial ablation of patients without other indications for anti-thrombotic therapy is highly variable. Further studies are necessary to evaluate the safest approach to these procedures.


  • Open Access

    Primary prevention implantable cardioverter-defibrillator use in non-ischemic dilated cardiomyopathy based on arrhythmic risk stratification and left ventricular reverse remodeling prediction

    by Ahmed Muhammed, Mohamed Abdelazeem, Mohamed Gamaleldin Elewa, Mohamed Sharief, Ahmed Ammar

    Sudden cardiac death (SCD) and significant ventricular arrhythmias in patients with dilated cardiomyopathy (DCM) have been markedly reduced over the last couple of decades as a result of the advances in pharmacological and non-pharmacological treatment. Primary prevention implantable cardioverter-defibrillator (ICD) plays an important role in the treatment of patients at risk of SCD caused by ventricular arrhythmias. However, the arrhythmic risk stratification in patients with DCM remains extremely challenging, and the decision for primary prevention ICD implantation based on left ventricular ejection fraction (LVEF) solely appears to be insufficient. This review provides an update on current evidence for primary prevention ICD implantation, arrhythmic risk stratification, and left ventricular reverse remodeling (LVRR) prediction in patients with DCM in addition to most recent guideline recommendations for primary prevention ICD implantation in DCM patients and a proposed multiparametric algorithm based on arrhythmic risk stratification and left ventricular reverse remodeling (LVRR) prediction to better identify patients who are likely to benefit from primary prevention ICD.